Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

86 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
How comparable are patient outcomes in the "real-world" with populations studied in pivotal AML trials?
Tiong IS, Wall M, Bajel A, Kalro A, Fleming S, Roberts AW, Thiagarajah N, Chua CC, Latimer M, Yeung D, Marlton P, Johnston A, Enjeti A, Fong CY, Cull G, Larsen S, Kennedy G, Schwarer A, Kipp D, Ramanathan S, Verner E, Tiley C, Morris E, Hahn U, Moore J, Taper J, Purtill D, Warburton P, Stevenson W, Murphy N, Tan P, Beligaswatte A, Mutsando H, Hertzberg M, Shortt J, Szabo F, Dunne K, Wei AH; Australasian Leukaemia and Lymphoma Group (ALLG). Tiong IS, et al. Among authors: szabo f. Blood Cancer J. 2024 Mar 26;14(1):54. doi: 10.1038/s41408-024-00996-x. Blood Cancer J. 2024. PMID: 38531863 Free PMC article.
Breakthrough fusariosis presenting initially with pyomyositis.
Zhu A, Htet S, Kalro A, Szabo F. Zhu A, et al. Among authors: szabo f. Pathology. 2017 Jan;49(1):105-107. doi: 10.1016/j.pathol.2016.10.007. Epub 2016 Nov 30. Pathology. 2017. PMID: 27914686 No abstract available.
A randomised evaluation of low-dose cytosine arabinoside (ara-C) plus tosedostat versus low-dose ara-C in older patients with acute myeloid leukaemia: results of the LI-1 trial.
Dennis M, Burnett A, Hills R, Thomas I, Ariti C, Severinsen MT, Hemmaway C, Greaves P, Clark RE, Copland M, Russell N; National Cancer Research Institute (NCRI) acute myeloid leukaemia (AML) Working Group. Dennis M, et al. Br J Haematol. 2021 Jul;194(2):298-308. doi: 10.1111/bjh.17501. Epub 2021 May 7. Br J Haematol. 2021. PMID: 33961292 Clinical Trial.
Carfilzomib, thalidomide, and dexamethasone is safe and effective in relapsed and/or refractory multiple myeloma: final report of the single arm, multicenter phase II ALLG MM018/AMN002 study.
Ninkovic S, Harrison SJ, Lee JJ, Murphy N, Lee JH, Estell J, Chen VM, Horvath N, Kim K, Eek R, Augustson B, Bang SM, Huang SY, Rajagopal R, Szabo F, Engeler D, Butcher BE, Mollee P, Durie B, Chng WJ, Quach H. Ninkovic S, et al. Among authors: szabo f. Haematologica. 2024 Jan 18. doi: 10.3324/haematol.2023.284238. Online ahead of print. Haematologica. 2024. PMID: 38235519 Free article.
Necrobiotic xanthogranuloma: response to chlorambucil.
Ryan E, Warren LJ, Szabo F. Ryan E, et al. Among authors: szabo f. Australas J Dermatol. 2012 May;53(2):e23-5. doi: 10.1111/j.1440-0960.2010.00710.x. Epub 2010 Oct 20. Australas J Dermatol. 2012. PMID: 22571578
The importance of frailty assessment in multiple myeloma: a position statement from the Myeloma Scientific Advisory Group to Myeloma Australia.
Sim S, Kalff A, Tuch G, Mollee P, Ho PJ, Harrison S, Gibbs S, Prince HM, Spencer A, Joshua D, Lee C, Ling S, Murphy N, Szabo F, Szer J, Weber N, Ward C, Talaulikar D, Zannettino A, Quach H. Sim S, et al. Among authors: szabo f. Intern Med J. 2023 May;53(5):819-824. doi: 10.1111/imj.16049. Epub 2023 May 10. Intern Med J. 2023. PMID: 36880355 Review.
86 results